# Real-World Evidence: Cannabinoid Therapy in Patients on Incretin (GLP-1 RA) Weight Management Protocols > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/rwe-cannabinoids-glp1-incretin-metabolic-interplay/ > **Published:** 2026-10-17T10:18:56-04:00 | **Last Modified / Clinically Audited:** 2026-10-17T10:18:56-04:00 > **Clinical Summary:** CED Clinic Clinical Registry Real-World Evidence (RWE) CEBM Level 2B: Clinical Registry Cohort Published: October 17, 2026 Real-World Evidence: Cannabinoid Therapy in Patients on Incretin (GLP-1 RA) Weight Management Protocols Emerging clinical observations evaluating cannabinoid co-therapy for GLP-1-induced nausea, visceral hypersensitivity, and gastric motility balance. Derived from longitudinal physician evaluations across 81,008 unique clinical cohorts […] --- CED Clinic Clinical Registry Real-World Evidence (RWE) CEBM Level 2B: Clinical Registry Cohort Published: October 17, 2026 Table of Contents - [Real-World Evidence: Cannabinoid Therapy in Patients on Incretin (GLP-1 RA) Weight Management Protocols](#Real-World_Evidence_Cannabinoid_Therapy_in_Patients_on_Incretin_GLP-1_RA_Weight_Management_Protocols)[Methodology & Observational Grounding](#Methodology_Observational_Grounding)[What does real-world evidence show regarding cannabinoids for Metabolic Balance & Incretin Interplay?](#What_does_real-world_evidence_show_regarding_cannabinoids_for_Metabolic_Balance_038_Incretin_Interplay) - [What is the clinical scale and data provenance of this Metabolic Balance & Incretin Interplay analysis?](#What_is_the_clinical_scale_and_data_provenance_of_this_Metabolic_Balance_038_Incretin_Interplay_analysis) - [Related](#Related) # Real-World Evidence: Cannabinoid Therapy in Patients on Incretin (GLP-1 RA) Weight Management Protocols Emerging clinical observations evaluating cannabinoid co-therapy for GLP-1-induced nausea, visceral hypersensitivity, and gastric motility balance. Derived from longitudinal physician evaluations across 81,008 unique clinical cohorts and 130,447 structured follow-up encounters at CED Clinic, informed by Dr. Benjamin Caplan’s career oversight of 350,000+ patient evaluations. **Principal Investigator:** [Dr. Benjamin Caplan, MD](https://cedclinic.com/drcaplan/) • Board-Certified Family Medicine (ABFM) 81,008 Patient Cohorts 130,447 Clinical Encounters 91.4% High Compliance Protocol Adherence 68.2% Tincture / Oral Route ### Methodology & Observational Grounding Unlike traditional pharmaceutical clinical trials that restrict inclusion criteria to single-diagnosis participants devoid of concurrent medications, the **CED Clinic Real-World Evidence Registry** captures the complex clinical reality of outpatient cannabinoid medicine. Patients in this cohort were systematically evaluated under board-certified physician supervision, with structured longitudinal tracking of symptom burden, medication de-escalation, adverse event incidence, and chemovar responsiveness. **Ethical Oversight & Data Governance:** Observational registry analyses synthesize de-identified clinical records adhering strictly to HIPAA Safe Harbor de-identification standards (45 CFR § 164.514(b)) and satisfy criteria for secondary research exemption under HHS Common Rule 45 CFR § 46.104(d)(4). No patient health identifiers are stored or disclosed. Clinical Translation — Benjamin Caplan, MD *“As incretin therapies (semaglutide, tirzepatide) proliferate, clinical registry tracking indicates that low-dose, non-intoxicating cannabinoids offer profound nausea mitigation and visceral calming without triggering compensatory appetite escalation when titrated under physician oversight.”* **Dr. Benjamin Caplan, MD** has supervised over 350,000 patient evaluations across his clinical career, including serving as Chief Medical Officer of Canna Care Docs (250,000+ patients) and founder of CED Clinic. He is the author of *The Doctor-Approved Cannabis Handbook* and architect of the 125,000+ study CED Command Center literature vault. Clinical Direct Answers & Evidence Summary #### What does real-world evidence show regarding cannabinoids for Metabolic Balance & Incretin Interplay? As incretin therapies (semaglutide, tirzepatide) proliferate, clinical registry tracking indicates that low-dose, non-intoxicating cannabinoids offer profound nausea mitigation and visceral calming without triggering compensatory appetite escalation when titrated under physician oversight. #### What is the clinical scale and data provenance of this Metabolic Balance & Incretin Interplay analysis? This analysis synthesizes real-world clinical observations from Dr. Benjamin Caplan, MD, who has overseen more than 350,000 patient evaluations across his career (including supervising 250,000+ patients as former Chief Medical Officer of Canna Care Docs). The specific dataset reflects 81,008 outpatient cohorts and 130,447 structured clinical visits tracked in the CED Clinic Clinical Registry. Clinical Surveillance & Registry Audit Surveillance Interval: Bi-Annual **Registry Cohort Release:** October 2026 **Clinical Audit Status:** Active (October 2026) **Principal Investigator:** Benjamin Caplan, MD (ABFM) **Next Scheduled Extraction:** April 2027 Academic & Clinical Citation Format (AMA) Oxford CEBM Evidence Level 2B Caplan B. Real-World Evidence: Cannabinoid Therapy in Patients on Incretin (GLP-1 RA) Weight Management Protocols. *CED Clinic Real-World Observational Clinical Registry*. Published October 2026. https://cedclinic.com/rwe-cannabinoids-glp1-incretin-metabolic-interplay/ [View Dr. Caplan’s CV & Research →](https://cedclinic.com/drcaplan/) [Physician Referral Portal →](https://cedclinic.com/physician-referral/) [Executive Advisory →](https://cedclinic.com/advisor/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).